Source: Seeking Alpha
Johnson & Johnson (NYSE:JNJ)
Q2 2014 Earnings Conference Call
July 15, 2014 8:30 AM ET
Executives
Louise Mehrotra – VP of IR
Alex Gorsky – Chairman of The Board of Directors and CEO
Joaquin Duato – Worldwide Chairman, Pharmaceuticals
Paul Stoffels – CSO, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals
Dominic Caruso – VP, Finance and CFO
Analysts
Matthew Dodds – Citigroup
Michael Weinstein – JP Morgan
Derrick Sung – Sanford Bernstein
Larry Biegelsen – Wells Fargo
Matt Miksic – Piper Jaffray
Josh Jennings – Cowen & Co.
Rick Wise – Stifel
Glenn Novarro – RBC Capital Markets
Bruce Nudell – Credit Suisse
David Lewis – Morgan Stanley
Kristen Stewart – Deutsche Bank
Jay Olson – Goldman Sachs
Operator
Good morning, and welcome to the Johnson & Johnson Second Quarter 2014 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. (Operator Instructions).
I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Louise Mehrotra – VP of IR
Good morning and welcome. I’m Louise Mehrotra, Vice President of Investor Relations for Johnson & Johnson and it is my pleasure this morning to review our business results for the second quarter of 2014. Joining me on the call today are Alex Gorsky, Chairman of The Board of Directors and Chief Executive Officer; Joaquin Duato, Worldwide Chairman, Pharmaceuticals; Paul Stoffels, Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Pharmaceuticals; and Dominic Caruso, Vice President, Finance and Chief Financial Officer. A few logistics before we get into the details.
This review is being made available via webcast accessible through the Investor Relations section of the Johnson & Johnson Web site. I’ll begin by briefly reviewing second quarter results for the corporation and for our three business segments. Following my remarks, Alex will provide some additional commentary on the business and an update on our near term priorities. Next, Joaquin and Paul will provide an update on our pharmaceutical business, and lastly Dominic will review the income statement and provide guidance for 2014.
Pages: First |1 | ... | Next → | Last | View Full Transcript